Skip to content

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00718744
Enrollment
30
Registered
2008-07-21
Start date
2008-06-30
Completion date
2008-11-30
Last updated
2010-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Conjunctivitis, Allergic, Rhinitis, Allergic, Seasonal

Keywords

Allergen-extract, Standardization

Brief summary

The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

Detailed description

The skin testing procedure, based on the Nordic Guidelines is the reference method for the biological calibration of in-House Reference Preparations (IHRP). The method is not intended for routine testing of allergen extracts. The use of this procedure is the basis for the definition of biological activity units: the activity of an allergen extract is 10,000 Biological Units (BU) per ml (10 HEP per ml), when the extract provokes an specific skin reaction in the median sensitive patient with a wheal of the same size as a wheal provoked by a positive reference solution consisting of histamine 54.3 mmol/l (for example histamine dihydrochloride 10 mg/ml), when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are clinically allergic and cutaneously reactive to the allergen concerned.

Interventions

OTHERStandardization of allergenic extract (Ch. arcuatus)

Allergenic extract for cutaneous prick-test

Sponsors

Laboratorios Leti, S.L.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Voluntarily signed informed consent form by the patient * Patients should live in a geographic zone where allergy caused by Chortoglyphus arcuatus is a relevant problem. * Patients should not be excluded due to low or high sensitivity to the allergen, when they otherwise fulfil the inclusion criteria. * A positive case history with inhalant allergy related to exposure to the allergen to be tested. * A positive prick test (mean wheal diameter \> 3 mm) when tested with a standardized extract prepared from the allergen source in question and/or a positive test for specific IgE. * A mean wheal diameter \> 7 mm2 obtained in a prick test with histamine dihydrochloride 10 mg/ml. * Age: 18-50 years. * Both genders

Exclusion criteria

* Immunotherapy in the past 2 years with an allergen preparation known to interfere with the allergens to be tested. * Use of drugs that may interfere with the skin reactions. * Pregnancy * Dermographism * Atopic dermatitis (locally at the test site) * Urticaria.

Design outcomes

Primary

MeasureTime frame
Wheal size area (mm2) of the immediate phase reaction.30 minutes per subject

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026